ReviewContemporary oncology (Poznan, Poland)2015
Rhabdomyosarcoma of the head and neck in children.
Review in Contemporary oncology (Poznan, Poland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Head and Neck Rhabdomyosarcoma in Children: An Otolaryngological Perspective on Diagnostic and Therapeutic Approaches.Current oncology reports · 2026Review
- Surgical Management of Pediatric Head and Neck Sarcoma: A Single-Centre Retrospective Analysis over a 10-Year Period.Journal of clinical medicine · 2026Article
- A Clearer Picture: Using Fetal MRI to Diagnose Neck Masses and Predict Airway Compromise.Prenatal diagnosis · 2026Article
- CAR-T cell immunotherapy in rhabdomyosarcoma.Journal of translational medicine · 2026Review
- Indications and Limits of Endoscopic Endonasal Approaches in Pediatric Neurosurgery.Advances and technical standards in neurosurgery · 2026Review
- Prognostic factors in pediatric head and neck rhabdomyosarcoma: a 30-year retrospective study in Brazil.Brazilian oral research · 2026Article
- Article
- Malignant and Benign Head and Neck Tumors of the Pediatric Age: A Narrative Review.Current pediatric reviews · 2025Review
- Rhabdomyosarcoma of the skull with EWSR1 fusion and ALK and cytokeratin expression: a case report.Journal of pathology and translational medicine · 2024Article
- Correlation of Genetic Polymorphism of CYP3A5 to Cyclophosphamide Efficacy and Toxicity in Rhabdomyosarcoma Pediatric Egyptian Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Congenital Tooth Agenesis and Risk of Early-Onset Cancer.JAMA network open · 2024Article
- Paediatric head and neck malignant neoplasms: A brazilian retrospective study.Medicina oral, patologia oral y cirugia bucal · 2023Article
- Cancer Stem Cell Markers in Rhabdomyosarcoma in Children.Diagnostics (Basel, Switzerland) · 2022Article
- International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.Ecancermedicalscience · 2022Article
- Review
- When a stuffy nose won't go away: Rhabdomyosarcoma masquerading as adenoiditis.Radiology case reports · 2021Article
- Sinonasal Rhabdomyosarcoma Metastasis in Bilateral Multiple Extraocular Muscles: A Case Report and Brief Literature Review.Taehan Yongsang Uihakhoe chi · 2021Article
- Incidental Hamartoma in an elderly patient: a case report.BMC ophthalmology · 2020Article
- The expanded endonasal approach in pediatric skull base surgery: A review.Laryngoscope investigative otolaryngology · 2020Review
- Prognostic Factors in Patients with Rhabdomyosarcoma Using Competing-Risks Analysis: A Study of Cases in the SEER Database.Journal of oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children. It is localized in the head and neck region in 40% of cases. Treatment of RMS is complex, including multi-drug chemotherapy, radiotherapy and surgery. The progress that has been accomplished in oncology in recent decades significantly improved outcomes. The 5-year survival rate raised from 25% in 1970 to 73% in 2001, according to IRS-IV data. The outcome is influenced by primary tumor localization, clinical staging, histological tumor type and age at the moment of diagnosis. The relatively rare incidence of these tumors resulted in difficulties in creating more standardized therapeutic protocols. Comparison of outcomes in large patients groups led to an increase in the number of patients with complete remission. Although survival rates of RMS patients have improved, searching for new therapeutic modalities and substances is still essential to improve outcomes in cases of more advanced stages and unfavorable tumor localizations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.